As a global provider of licensed cannabis genetics and seeds, our focus is on developing genetics and producing registered seeds and cultivars through ambitious research and development programs. With our expertise, knowledge, and necessary permits as a formal cannabis genetics producer and supplier, we are in a privileged position for global operations. Established in 2016, medcann Pharma is driven by two main pillars: a deep understanding of the Colombian regulatory framework and decades of experience in hybridization, cultivation, and transformation of cannabis for medicinal purposes.

Starting from 2021, our company is also concentrating on cannabis genetics to offer the highest quality, legal, and formalized genetic varieties globally. By leveraging the latest in molecular genomic technology and continuous research and development, we ensure a diverse and growing catalog to meet market needs. With competitive advantages such as our excellent geographical location, providers of legally and traceable genetics, continuous genetic improvements, and strong corporate governance practices, medcann Pharma aims to be a leading supplier in the cannabis and hemp industry worldwide.

Our production and operations center in Fuentedeoro, Colombia spans over 23 hectares of land, including 10 hectares of field cultivation, reservoirs with approximately 30,000 m3 capacity, and four laboratories dedicated to seeds, tissues, quality, and transformation. We are committed to implementing biological cultivation practices with beneficial microbes and enzymes. As part of the medcann Pharma Inc.

Group, headquartered in Canada with subsidiaries in Spain, Peru, and Colombia, we are one of the few companies globally registered as a provider of formalized genetics. To learn more about our brand, genetics, research and development, or investment opportunities, please visit our website or contact us directly